Publications by authors named "Yuusuke Morita"
Article Synopsis
- Ramucirumab is a targeted therapy for advanced hepatocellular carcinoma (HCC) in patients with high levels of alpha-fetoprotein (AFP) after failing initial treatments, particularly Sorafenib.
- A study of 33 patients revealed that improving albumin-bilirubin (ALBI) scores during treatment correlated with better outcomes and prognosis.
- Patients who continued treatment after ramucirumab failure and had good ALBI scores at the beginning saw significantly better prognoses compared to those who did not pursue further therapy.
